{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:51:16Z","timestamp":1782168676361,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008459","name":"University of Calgary","doi-asserted-by":"publisher","award":["NCT01339455"],"award-info":[{"award-number":["NCT01339455"]}],"id":[{"id":"10.13039\/100008459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.msard.2021.102990","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T12:53:32Z","timestamp":1620132812000},"page":"102990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-9535","authenticated-orcid":false,"given":"Jodie M.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanne","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2021.102990_bib0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2021.102990_bib0003","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.102990_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(09)70017-1","article-title":"Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I\/II study","volume":"8","author":"Burt","year":"2009","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2021.102990_bib0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/acn3.50843","article-title":"T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica","volume":"6","author":"Ceglie","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"10206","key":"10.1016\/j.msard.2021.102990_bib0006","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102990_bib0007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102990_bib0008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT autoimmune diseases working party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102990_bib0009","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24079","article-title":"Allogenic hematopoietic stem cell transplantation for neuromyelitis optica","volume":"75","author":"Greco","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102990_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102110","article-title":"Allogeneic haematopoietic stem cell transplantation in a refractory case of neuromyelitis optica spectrum disorder","volume":"42","author":"Hau","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102990_bib0011","first-page":"26","article-title":"Autologous hematopoietic stem cell transplantation for the treatment of neuromyelitis optica in Singapore","volume":"27","author":"Hoay","year":"2018","journal-title":"Acta Neurol. Taiwan"},{"key":"10.1016\/j.msard.2021.102990_bib0012","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2021.102990_bib0013","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2021.102990_bib0014","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneurol.2011.38","article-title":"Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica","volume":"68","author":"Matiello","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2021.102990_bib0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.102990_bib0016","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0000000000000531","article-title":"Application of stem cell transplantation to autoimmune disease","volume":"26","author":"Ng","year":"2019","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"10.1016\/j.msard.2021.102990_bib0017","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2021.102990_bib0018","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NRL.0b013e3181b126e3","article-title":"A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation","volume":"16","author":"Peng","year":"2010","journal-title":"Neurologist"},{"key":"10.1016\/j.msard.2021.102990_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.msard.2021.102990_bib0020","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"(NOMADMUS study group). Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102990_bib0021","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transp."},{"issue":"5","key":"10.1016\/j.msard.2021.102990_bib0022","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2021.102990_bib0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102990_bib0024","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2021.102990_bib0025","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"G. Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2021.102990_bib0026","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102990_bib0001","unstructured":"Brooks, J., Atkins, H., Bose, G., Thebault, S., Freedman, M., Rush, C. Autologous hematopoietic stem cell transplant in patients with severe refractory neuromyelitis optica spectrum disorder. ECTRIMS Online Library. Brooks J. 09\/12\/2019; 279442; 143."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:40Z","timestamp":1761901120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":26,"alternative-id":["S2211034821002571"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102990","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102990"}}